Clinical Trials
Below is a listing of clinical trials conducted at MUSC Hollings Cancer Center. Use the tools in the left toolbar to refine your search. If you are interested in Early Phase/Multi Tumor trials, select the program “Phase I Unit.” Please note that cohort information for the Phase I trials changes often.
| Protocol | Title | Status | Docs |
|---|---|---|---|
| 104387 | A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants with Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma | OPEN TO ACCRUAL |
|
| 104318 | Randomized Study of Resection and GammaTile Followed by Concurrent External Beam Radiation Therapy (ERBT) and Temozolomide (TMZ) and Adjuvant TMZ Versus Standard of Care in Newly Diagnosed Glioblastoma (GBM) | OPEN TO ACCRUAL |
|
| 104160 | BCC021- Phase I/II Study of Silmitasertib (CX-4945) in Combination with Chemotherapy in Children and Young Adults with Relapsed Refractory Solid Tumors | OPEN TO ACCRUAL |
|
| 104306 | A Phase 1 Open-Label, Multicenter Study of JANX014 in Participants with Prostate Cancer | OPEN TO ACCRUAL |
|
| 104311 | A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants with Low Grade Upper Tract Urothelial Carcinoma (SURF303) | OPEN TO ACCRUAL |
|
| 104396 | A Phase III Trial of Rx Therapy Guided by Genomic Risk Assessment For High Anatomic Stage ER-pos/HER2-neg Breast Cancer with RS25 (RxFINE-Low) | OPEN TO ACCRUAL |
|
| 104354 | Comparing Oral Drug Dosing Strategies in Older Patients with Metastatic Breast Cancer to Maximize Tolerance and Reduce Discontinuation: The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | OPEN TO ACCRUAL |
|
| 104302 | A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physicians Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma | OPEN TO ACCRUAL |
|
| 104399 | Radiotherapy with Concurrent Cetuximab vs. Carboplatin and Paclitaxel in Patients with Locoregionally Advanced Head and Neck Cancer with aContraindication to Cisplatin: A Pragmatic Phase III Randomized Trial (CONCISE) | OPEN TO ACCRUAL |
|
| 104291 | A Phase 3, Open-Label, Randomized Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | OPEN TO ACCRUAL |
|
| 104230 | Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT) | OPEN TO ACCRUAL |
|
| 104305 | A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02:01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301) | OPEN TO ACCRUAL |
|
| 104199 | A Phase I, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AT03-65 in Adults with Advanced Solid Tumors | OPEN TO ACCRUAL |
|
| 104246 | A Phase 2, Single-Arm Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 1) | OPEN TO ACCRUAL |
|
| 104044 | Neo-TILs: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Triple Negative Breast Cancer (TNBC) Patients with Elevated Tumor-Infiltrating Lymphocytes (TILs) | OPEN TO ACCRUAL |
|
| 104359 | A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients With Relapsed and Refractory Multiple Myeloma | OPEN TO ACCRUAL |
|
| 104233 | A Phase 1, First-in-Human, Open-label, Multicenter Study of JZP898 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors | OPEN TO ACCRUAL |
|
| 104365 | PHASE III TRIAL OF RADIOTHERAPY FOLLOWED BY ADJUVANT TEMOZOLOMIDE IN COMBINATION WITH THE IDH INHIBITOR VORASIDENIB VS. PLACEBO IN IDH-MUTATED NEWLY-DIAGNOSED GRADE 3 ASTROCYTOMAS | OPEN TO ACCRUAL |
|
| 104286 | A Phase II Study of Combined Amivantamab, Carboplatin and Paclitaxel in Unresectable Locally Recurrent or Metastatic Head and Neck Cancer | OPEN TO ACCRUAL |
|
| 104245 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients with Refractory Advanced/Metastatic Microsatellite Stable Colorectal Cancer | OPEN TO ACCRUAL |
|